메뉴 건너뛰기




Volumn 167, Issue 5, 2014, Pages 646-652

Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion

(16)  Ezekowitz, Michael D a,b   Cappato, Riccardo c,j   Klein, Allan L d   Camm, A John e   Ma, Chang Sheng f   Le Heuzey, Jean Yves g   Talajic, Mario h   Scanavacca, Maurício I i   Vardas, Panos E j   Kirchhof, Paulus k,l   Hohnloser, Stefan H m   Hemmrich, Melanie n   Lanius, Vivian o   Meng, Isabelle Ling p   Wildgoose, Peter q   Van Eickels, Martin p  


Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; FLUINDIONE; PHENPROCOUMON; RIVAROXABAN; WARFARIN;

EID: 84899547365     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.12.024     Document Type: Article
Times cited : (22)

References (19)
  • 1
    • 0020964823 scopus 로고
    • Coronary heart disease and atrial fibrillation: The Framingham study
    • W.B. Kannel, R.D. Abbott, and D.D. Savage et al. Coronary heart disease and atrial fibrillation: the Framingham study Am Heart J 106 1983 389 396
    • (1983) Am Heart J , vol.106 , pp. 389-396
    • Kannel, W.B.1    Abbott, R.D.2    Savage, D.D.3
  • 2
    • 0035832261 scopus 로고    scopus 로고
    • Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study
    • A.S. Go, E.M. Hylek, and K.A. Phillips et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study JAMA 285 2001 2370 2375
    • (2001) JAMA , vol.285 , pp. 2370-2375
    • Go, A.S.1    Hylek, E.M.2    Phillips, K.A.3
  • 3
    • 0034778819 scopus 로고    scopus 로고
    • Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study
    • S. Stewart, C.L. Hart, and D.J. Hole et al. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study Heart 86 2001 516 521
    • (2001) Heart , vol.86 , pp. 516-521
    • Stewart, S.1    Hart, C.L.2    Hole, D.J.3
  • 4
    • 0029984410 scopus 로고    scopus 로고
    • Management of patients with atrial fibrillation. A statement for healthcare professionals. from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association
    • E.N. Prystowsky, D.W. Benson Jr., and V. Fuster et al. Management of patients with atrial fibrillation. A statement for healthcare professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association Circulation 93 1996 1262 1277
    • (1996) Circulation , vol.93 , pp. 1262-1277
    • Prystowsky, E.N.1    Benson, Jr.D.W.2    Fuster, V.3
  • 5
    • 77957699729 scopus 로고    scopus 로고
    • Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)
    • A.J. Camm, P. Kirchhof, and G.Y.H. Lip et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429
    • (2010) Eur Heart J , vol.31 , pp. 2369-2429
    • Camm, A.J.1    Kirchhof, P.2    Lip, G.Y.H.3
  • 6
    • 79953038399 scopus 로고    scopus 로고
    • 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
    • V. Fuster, L.E. Rydén, and D.S. Cannom et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 123 2011 e269 e367
    • (2011) Circulation , vol.123
    • Fuster, V.1    Rydén, L.E.2    Cannom, D.S.3
  • 7
    • 84856745317 scopus 로고    scopus 로고
    • Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
    • J.J. You, D.E. Singer, and P.A. Howard et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines Chest 141 2012 e531S e575S
    • (2012) Chest , vol.141
    • You, J.J.1    Singer, D.E.2    Howard, P.A.3
  • 8
    • 0035837496 scopus 로고    scopus 로고
    • Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation
    • A.L. Klein, R.A. Grimm, and R.D. Murray et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation N Engl J Med 344 2001 1411 1420
    • (2001) N Engl J Med , vol.344 , pp. 1411-1420
    • Klein, A.L.1    Grimm, R.A.2    Murray, R.D.3
  • 9
    • 80052592404 scopus 로고    scopus 로고
    • Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
    • M.R. Patel, K.W. Mahaffey, and J. Garg et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
    • (2011) N Engl J Med , vol.365 , pp. 883-891
    • Patel, M.R.1    Mahaffey, K.W.2    Garg, J.3
  • 10
    • 80052825103 scopus 로고    scopus 로고
    • Apixaban versus warfarin in patients with atrial fibrillation
    • C.B. Granger, J.H. Alexander, and J.J. McMurray et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
    • (2011) N Engl J Med , vol.365 , pp. 981-992
    • Granger, C.B.1    Alexander, J.H.2    McMurray, J.J.3
  • 11
    • 70349306707 scopus 로고    scopus 로고
    • Dabigatran versus warfarin in patients with atrial fibrillation
    • S.J. Connolly, M.D. Ezekowitz, and S. Yusuf et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
    • (2009) N Engl J Med , vol.361 , pp. 1139-1151
    • Connolly, S.J.1    Ezekowitz, M.D.2    Yusuf, S.3
  • 12
    • 78751637313 scopus 로고    scopus 로고
    • Dabigatran versus warfarin in patients with atrial fibrillation: An analysis of patients undergoing cardioversion
    • R. Nagarakanti, M.D. Ezekowitz, and J. Oldgren et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion Circulation 123 2011 131 136
    • (2011) Circulation , vol.123 , pp. 131-136
    • Nagarakanti, R.1    Ezekowitz, M.D.2    Oldgren, J.3
  • 13
    • 84877276344 scopus 로고    scopus 로고
    • Outcomes following cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial
    • J.P. Piccini, S.R. Stevens, and Y. Lokhnygina et al. Outcomes following cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial J Am Coll Cardiol 61 2013 1998 2006
    • (2013) J Am Coll Cardiol , vol.61 , pp. 1998-2006
    • Piccini, J.P.1    Stevens, S.R.2    Lokhnygina, Y.3
  • 14
    • 84893362981 scopus 로고    scopus 로고
    • Efficacy and safety of apixaban in patients following cardioversion for atrial fibrillation: Insights from the ARISTOTLE trial
    • [ePub]
    • G. Flaker, R.D. Lopes, and S.M. Al-Khatib et al. Efficacy and safety of apixaban in patients following cardioversion for atrial fibrillation: insights from the ARISTOTLE trial J Am Coll Cardiol 2013 [ePub]
    • (2013) J Am Coll Cardiol
    • Flaker, G.1    Lopes, R.D.2    Al-Khatib, S.M.3
  • 16
    • 79951853372 scopus 로고    scopus 로고
    • Boehringer Ingelheim International Gmbh Last accessed November 18, 2013
    • Boehringer Ingelheim International GmbH Pradaxa (dabigatran etexilate) summary of product characteristics http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/000829/WC500041059.pdf 2013 Last accessed November 18, 2013
    • (2013) Pradaxa (Dabigatran Etexilate) Summary of Product Characteristics
  • 17
    • 84892592709 scopus 로고    scopus 로고
    • Last accessed November 18, 2013
    • Bristol-Myers Squibb, and Pfizer EEIG Eliquis (apixaban) summary of product characteristics http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/002148/WC500107728.pdf 2013 Last accessed November 18, 2013
    • (2013) Eliquis (Apixaban) Summary of Product Characteristics
    • Squibb, B.1    Eeig, P.2
  • 18
    • 23044505564 scopus 로고    scopus 로고
    • Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
    • S. Schulman, and C. Kearon Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 3 2005 692 694
    • (2005) J Thromb Haemost , vol.3 , pp. 692-694
    • Schulman, S.1    Kearon, C.2
  • 19
    • 0016916438 scopus 로고
    • Prediction of creatinine clearance from serum creatinine
    • D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
    • (1976) Nephron , vol.16 , pp. 31-41
    • Cockcroft, D.W.1    Gault, M.H.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.